SGD Pharma, global provider of molded glass primary packaging solutions for the pharmaceutical industry, introduced its new range of Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning under an exclusive co-development partnership. SGD Pharma’s vial-converting expertise is combined with Corning’s glass-coating technology with the aim to improve pharmaceutical filling-line productivity and speed for the global delivery of injectable treatments.

SGD Pharma’s new Velocity Vial offering aims to reduce the frictional resistance created by glass-to-glass and glass-to-metal contact, helping pharmaceutical filing lines to prevent potential disruptions to the flow of vials, which can include tip-overs, jams and glass breakages. According to the company, this results in a reduction in total cost of ownership and an increase in glass quality, making the fill and finish process 20-50% more efficient.

Additionally, SGD Pharma’s Velocity Vials are designed to reduce glass particulates up to 96% with minimal risk of glass particulates getting trapped inside vials during fill and finish operations. 

The Type I tubular glass vials are compliant with USP and EP requirements and are manufactured and released in accordance with ISO GMP standards. The Velocity Vial coating technology is available in both clear and amber glass, in standard vial sizes 2R to 20R (though sizes up to 30R can be made available on request) and is compliant with EU and U.S. health authorities.